Annemiek Broijl
Clinical studies and translational research in Multiple Myeloma
Annemiek Broijl has been a staff member of the Hematology department of the Erasmus MC Cancer Institute in Rotterdam since 2013. She is trained as a hematologist at the Department of Hematology at the Erasmus MC Cancer Institute and obtained her PhD cum laude in 2012 for her thesis 'Molecular Profiling in Multiple Myeloma' under the supervision of Professor Pieter Sonneveld. She plays an active role in the national myeloma working group (MWG), is a member of the International Myeloma Working Group (IMWG), and member and chair of the board of the Young European Myeloma Network (EMN).
Our research
The current activities of dr. Broijl are focused on organizing clinical trials in multiple myeloma with a strong correlative program. Her main interest lies in the molecular characterization of the disease and the patient, as well as the microenvironment of the bone marrow and the adaptive immune system in the patient to identify disease and patient-related factors involved in resistance/susceptibility to therapy. She combines active patient care with translational studies in the hematology laboratory.
Our team
Annemiek Broijl, principal investigator
Pieter Sonneveld, principal investigator
Jasper Koenders, research technician
Michael Vermeulen, research technician
Lizzy Bestebreur, analist
Ramona Eysbach, analist
Naomi Leeuwestein, analist
Huda Yasmine, analist
Mark van Duin, postdoc
Marjolein Appelman, PhD student
Key publications
Fokkema C, Moreau P, Van der Holt B, Lambert J, Van Duin M, Wester R, Jongen JLM, Van Doorn PA, Godet S, Jie KS, Fitoussi O, Delforge M, Keita-Manta A, Luycx O, Cupedo T, Van de Donk NWCJ, Zweegman S, Vermeulen JT, Sonneveld P, Annemiek Broijl. Treatment emergent peripheral neuropathy in the CASSIOPEIA trial. Haematologica. 2022 Jul 1;107(7):1726-1730.
Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Annemiek Broijl, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Nov 10;39(32):3613-3622.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Annemiek Broijl, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Oct;22(10):1378-1390.
Noori S, Zajec M, Russcher H, Tintu AN, Annemiek Broijl, Jacobs JFM, Luider TM, de Rijke YB, vanDuijn MM. Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis. Hemasphere. 2022 Aug 2;6(8):e758.
de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste Op Bruinink D, Hoogenboezem R, Sanders MA, van de Woestijne PC, Bos PK, Khandanpour C, Vermeulen J, Moreau P, van Duin M, Annemiek Broijl, Sonneveld P, Cupedo T. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021 Jun;22(6):769-780.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Annemiek Broijl, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019 Jul 6;394(10192):29-38.
Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Annemiek Broijl, Sonneveld P. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 2019 Nov;104(11):2265-2273.
Annemiek Broijl, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica. 2016 Apr;101(4):e149-52.
Kuiper R, Annemiek Broijl, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012 Nov;26(11):2406-13.
Annemiek Broijl, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with trial. Lancet Oncol. 2010 Nov;11(11):1057-65.